Fanini D, Poglio M, Marci M C, Iovinelli G, Antenucci F
Corso di Laurea in Odontoiatria e Protesi Dentaria, Insegnamento di Farmacologia, Università degli Studi, L'Aquila.
Minerva Stomatol. 1998 Sep;47(9):453-64.
Clonidine, an alpha 2-adrenoceptor agonist, has been recently shown to be effective in conscious sedation because of its analgesic and sedative properties, having also proven to be active in reducing neuroendocrine responses to stressful stimuli perioperatively. The current study was designed to investigate the efficacy of 150 micrograms oral clonidine as a premedicant in dentistry.
In a prospective, randomized, double-blind controlled clinical trial, 40 patients, aged 16-64 yr, undergoing conservative, or prosthetic, or dental surgery procedures, received placebo (n = 20) or 150 micrograms of oral clonidine (n = 20) 90 min before the estimated time of induction of local anesthesia. A blinded observer recorded: salivary flow, systolic and diastolic blood pressure each 30 min lasting 2-3 hours, as well as the degree of pain and sedation intra and postoperatively.
Clonidine produced significant salivary flow reduction (p < 0.001) and sedation (p < 0.001) as well as significant difference in postoperative pain scores (p < 0.05) compared to placebo. Xerostomia persisted postoperatively in clonidine premedicated patients as compared to those given the placebo (p < 0.01). Systolic blood pressure decreased significantly only after 120 (p < 0.01) and 150 min (p < 0.001) following clonidine pretreatment, but none of the patients were treated for hypotension. 55% of the clonidine treated patients positively evaluated the experience.
These results suggest that a dose of 150 micrograms of clonidine, given orally 90 min preoperatively, is an effective premedication in dentistry, without causing excessive haemodynamic depression and sedation, and moreover confirm that the oral route of administration is very well accepted.
可乐定是一种α2肾上腺素能受体激动剂,最近因其镇痛和镇静特性被证明在清醒镇静中有效,还被证明在围手术期能有效降低对应激刺激的神经内分泌反应。本研究旨在调查150微克口服可乐定作为牙科术前用药的疗效。
在一项前瞻性、随机、双盲对照临床试验中,40例年龄在16 - 64岁、接受保守治疗、修复治疗或牙科手术的患者,在预计局部麻醉诱导时间前90分钟接受安慰剂(n = 20)或150微克口服可乐定(n = 20)。一名盲法观察者记录:唾液流量、收缩压和舒张压,每30分钟记录一次,持续2 - 3小时,以及术中和术后的疼痛程度和镇静程度。
与安慰剂相比,可乐定使唾液流量显著减少(p < 0.001)、产生镇静作用(p < 0.001),且术后疼痛评分有显著差异(p < 0.05)。与接受安慰剂的患者相比,可乐定预处理患者术后口干持续存在(p < 0.01)。可乐定预处理后仅在第120分钟(p < 0.01)和150分钟(p < 0.001)收缩压显著下降,但没有患者因低血压接受治疗。55%接受可乐定治疗的患者对该体验给予积极评价。
这些结果表明,术前90分钟口服150微克可乐定是牙科有效的术前用药,不会引起过度的血流动力学抑制和镇静,而且证实口服给药途径很容易被接受。